FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Costs across the US healthcare system of implementing new suffix-based nomenclature could reach into the billions, stakeholders say in requesting the Office of Management and Budget delay implementation of FDA’s final guidance on nonproprietary naming of biologics pending further analysis.
You may also be interested in...
How is the generic industry like Captain "Sully" trying to land a damaged plane in the Hudson River?
But even though executive order that requires regulatory off sets may only have limited application to FDA, limited, experts warn that it still could prove extremely unwieldly to implement.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.